Intranasal insulin

Intranasal Insulin Ameliorates Experimental Diabetic Neuropathy

OBJECTIVE We hypothesized that intranasal insulin (I-I) delivery targets the nervous system while avoiding potential adverse systemic effects when compared with subcutaneous insulin (S-I) for experimental streptozotocin-induced diabetic peripheral neuropathy (DPN). RESEARCH DESIGN AND METHODS I-I or S-I at 0.87 IU daily or placebo were delivered in separate cohorts of diabetic and nondiabetic...

Intranasal insulin neuroprotection in ischemic stroke

Targeting Mediators of Smoking Persistence with Intranasal Insulin

Rapid-acting, non-irritating nasal treatment options for smoking cessation pharmacotherapy are lacking. The halt in development is due, in part, to difficulty in delivering compounds across the blood brain barrier. Recently, in both human and animal models, insulin was shown to be capable of being transported to the cerebrospinal fluid and various brain regions via the "nose-to-brain" pathway, ...

New strategies to improve the intranasal absorption of insulin.

Recently, intranasal delivery of insulin as an alternative route of parenteral administration has been widely studied because it bears close resemblance to the 'pulsatile' pattern of endogenous insulin secretion during meal time. However, insulin is not well absorbed through nasal mucosa because of its large molecular size, hydrophilicity and low permeability through the membrane. This review d...

Intranasal insulin to treat and protect against posttraumatic stress disorder.

Lessons learned from research on the treatment of Alzheimer’s disease (AD) suggest a new strategy for treating posttraumatic stress disorder (PTSD). The NIH recently selected intranasal insulin as a promising treatment for AD and committed 7.9 million in funding to further test it nationally (Health and Human Services Press Office for Secretary Kathleen Sebelius, 2012). The noninvasive intranas...